{"id":"NCT02817841","sponsor":"Estetra","briefTitle":"E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study","officialTitle":"A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-30","primaryCompletion":"2018-10-16","completion":"2018-11-16","firstPosted":"2016-06-29","resultsPosted":"2019-11-06","lastUpdate":"2020-02-10"},"enrollment":2148,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"15 mg E4/3 mg DRSP","otherNames":["15 mg estetrol and 3 mg drospirenone"]}],"arms":[{"label":"15 mg E4/3 mg DRSP","type":"EXPERIMENTAL"}],"summary":"The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.","primaryOutcome":{"measure":"The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of Screening","timeFrame":"Up to 12 months (13 cycles with 1 cycle = 28 days)","effectByArm":[{"arm":"15 mg E4/3 mg DRSP","deltaMin":2.65,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":27},"locations":{"siteCount":2,"countries":["United States","Canada"]},"refs":{"pmids":["37023457"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":1864},"commonTop":["Headache","Metrorrhagia","Nausea","Dysmenorrhoea","Urinary tract infection"]}}